GlassScriptPhysician profile
Casey Farin Jeffreys
NPI 1619395092
$82,181.94
in general payments reported to CMS, 2019-2025
58 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $20K · 2021: $5,621 · 2022: $14K · 2023: $3,082 · 2024: $13K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $13K · Education: $225 · Travel and Lodging: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,923.00 |
| Food and Beverage | $12,615.37 |
| Education | $225.30 |
| Travel and Lodging | $202.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $26,840.36 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $15,343.35 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Genentech USA, INC. | $13,537.33 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $8,569.10 | 2019-2025 | |
| Genzyme Corporation | $5,552.39 | 2019-2025 | |
| Tg Therapeutics, INC. | $2,302.04 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $1,429.44 | 2019-2025 | Ultomiris, Soliris |
| Celgene Corporation | $956.28 | 2019-2025 | Zeposia |
| Abbvie INC. | $778.85 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $662.95 | 2020-2025 | Acthar |
| Ucb, INC. | $595.49 | 2023-2025 | Briviact, Rystiggo, Nayzilam |
| Amgen INC. | $535.02 | 2019-2025 | Uplizna, Aimovig |
| Argenx US, INC. | $502.73 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $499.90 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Pfizer INC. | $469.83 | 2022-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Jeffreys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.